The US Food and Drug Administration approved CSPC Pharmaceutical's (HKG:1093) clinical trials for its SYH2051 for advanced solid tumors, according to a Thursday filing with the Hong Kong exchange.
The drug is an ataxia telangiectasia mutated or ATM inhibitor, which delays the repair of DNA double-strand breaks in tumor cells, the filing said.
SYH2051 showed good selectivity of ATM targets, according to the filing.
The drug also obtained China approval for clinical trials in June 2023.
Shares rose 2% during Friday's afternoon trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。